Family with sequence similarity 83, member B is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild-type epidermal growth factor receptor.

Lung adenocarcinoma (ADC) patients with tumors that harbor no targetable driver gene mutation, such as epidermal growth factor receptor () gene mutations, have unfavorable prognosis, and thus, novel therapeutic targets are required. () is a biomarker for squamous cell lung cancer. FAM83B has also recently been shown to serve an important role in the EGFR signaling pathway. In the present study, the molecular and clinical impact of FAM83B in lung ADC was investigated. Matched tumor and adjacent normal tissue samples were obtained from 216 patients who underwent complete lung resection for primary lung ADC and were examined for expression using cDNA microarray analysis. The associations between expression and clinicopathological parameters, including patient survival, were examined. was highly expressed in tumors from males, smokers and in tumors with wild-type . Multivariate analyses further confirmed that wild-type tumors were significantly positively associated with expression. In survival analysis, expression was associated with poor outcomes in disease-free survival and overall survival, particularly when stratified against tumors with wild-type . Furthermore, knockdown was performed to investigate its phenotypic effect on lung ADC cell lines. Gene silencing by RNA interference induced growth suppression in the HLC-1 and H1975 lung ADC cell lines. may be involved in lung ADC tumor proliferation and can be a predictor of poor survival. is also a potential novel therapeutic target for ADC with wild-type .